Regulation of Atherogenesis by Chemokine Receptor CCR6

Trends in Cardiovascular Medicine

Volumn 21, Issue 5, 2011, Pages 140-144

  Wan, Wuzhou ^a   Murphy, Philip M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHEMOATTRACTANT; CHEMOKINE RECEPTOR CCR6; G PROTEIN COUPLED RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA;

ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CELL TYPE; HUMAN; IMMUNE RESPONSE; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; ATHEROSCLEROSIS; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, KNOCKOUT; RECEPTORS, CCR6;

EID: 84862747931     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.04.003     Document Type: Review

References (40)

1. Butcher M., Galkina E. Current views on the functions of interleukin-17A-producing cells in atherosclerosis. Thromb Haemost 2011, 106:787-795.
2. Butcher M.J., Galkina E.V. Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta. Front Physiol (Bethesda) 2012, 3:44.
3. Butcher M.J., Gjurich B.N., Phillips T., Galkina E.V. The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ Res 2012, 110:675-687.
4. Calvayrac O., Rodríguez-Calvo R., Alonso J., et al. CCL20 is increased in hypercholesterolemic subjects and is upregulated by LDL in vascular smooth muscle cells: Role of NF-κB. Arterioscler Thromb Vasc Biol 2011, 31:2733-2741.
5. Caux C., Ait-Yahia S., Chemin K., et al. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 2000, 22:345-369.
6. Comerford I., Bunting M., Fenix K., et al. An immune paradox: How can the same chemokine axis regulate both immune tolerance and activation? CCR6/CCL20: A chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. Bioessays 2010, 32:1067-1076.
7. Danzaki K., Matsui Y., Ikesue M., et al. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2012, 32:273-280.
8. Dieu M.C., Vanbervliet B., Vicari A., et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998, 188:373-386.
9. Doran A.C., Lipinski M.J., Oldham S.N., et al. B-cell aortic homing and atheroprotection depend on Id3. Circ Res 2012, 110:e1-e12.
10. Galkina E., Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009, 27:165-197.
11. Hedrick M.N., Lonsdorf A.S., Hwang S.T., Farber J.M. CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets 2010, 14:911-922.
12. Hedrick M.N., Lonsdorf A.S., Shirakawa A.K., et al. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest 2009, 119:2317-2329.
13. Hirota K., Yoshitomi H., Hashimoto M., et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007, 204:2803-2812.
14. Ito T.Carson W.F.4th, Cavassani K.A., et al. CCR6 as a mediator of immunity in the lung and gut. Exp Cell Res 2011, 317:613-619.
15. Kitas G.D., Gabriel S.E. Cardiovascular disease in rheumatoid arthritis: State of the art and future perspectives. Ann Rheum Dis 2011, 70:8-14.
16. Koenen R.R., Weber C. Chemokines: Established and novel targets in atherosclerosis. EMBO Mol Med 2011, 3:713-725.
17. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu Rev Immunol 2009, 27:485-517.
18. Kyaw T., Tipping P., Toh B.H., Bobik A. Current understanding of the role of B cell subsets and intimal and adventitial B cells in atherosclerosis. Curr Opin Lipidol 2011, 22:373-379.
19. + T cell crosspriming in vivo. Immunity 2006, 24:191-201.
20. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
21. Madhur M.S., Funt S.A., Li L., et al. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 2011, 31:1565-1572.
22. McDermott D.H., Liu Q., Ulrick J., et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood 2011, 118:4957-4962.
23. Murphy P.M., Baggiolini M., Charo I.F., et al. International union of pharmacology: XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000, 52:145-176.
24. Raines E.W., Ferri N. Thematic review series: The immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res 2005, 46:1081-1092.
25. Robertson A.K., Hansson G.K. T cells in atherogenesis: For better or for worse?. Arterioscler Thromb Vasc Biol 2006, 26:2421-2432.
26. Rosenfeld M.E., Campbell L.A. Pathogens and atherosclerosis: Update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost 2011, 106:858-867.
27. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999, 340:115-126.
28. Ruth J.H., Shahrara S., Park C.C., et al. Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis. Lab Invest 2003, 83:579-588.
29. Sallusto F., Schaerli P., Loetscher P., et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998, 28:2760-2769.
30. Schutyser E., Struyf S., Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003, 14:409-426.
31. Stahl E.A., Raychaudhuri S., Remmers E.F., et al. Genomewide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010, 42:508-514.
32. Stoneman V., Braganza D., Figg N., et al. Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ Res 2007, 100:884-893.
33. Surmi B.K., Hasty A.H. The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue. Vasc Pharmacol 2010, 52:27-36.
34. Wan W., Lim J.K., Lionakis M.S., et al. Genetic deletion of chemokine receptor Ccr6 decreases atherogenesis in ApoE-deficient mice. Circ Res 2011, 109:374-381.
35. Weber C., Noels H. Atherosclerosis: Current pathogenesis and therapeutic options. Nat Med 2011, 17:1410-1422.
36. Weber C., Zernecke A., Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat Rev Immunol 2008, 8:802-815.
37. Yamashiro S., Wang J.M., Yang D., et al. Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood 2000, 96:3958-3963.
38. Yamazaki T., Yang X.O., Chung Y., et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol 2008, 181:8391-8401.
39. Yilmaz A., Lipfert B., Cicha I., et al. Accumulation of immune cells and high expression of chemokines/chemokine receptors in the upstream shoulder of atherosclerotic carotid plaques. Exp Mol Pathol 2007, 82:245-255.
40. + T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000, 102:2919-2922.